We are live on
!
Find out more
PSC
Patient Square Capital Portfolio holdings
AUM
$564M
1-Year Est. Return
261.3%
This Fund
S&P 500
1 Year Est. Return
+261.3%
AUM
$564M
AUM Growth
+$96.5M
(+21%)
Holding
35
Top Buys
| 1 | +$19.6M | |
| 2 | +$18.9M | |
| 3 | +$12M | |
| 4 |
Cogent Biosciences
COGT
|
+$10.3M |
| 5 |
Merck
MRK
|
+$9.24M |
Top Sells
| 1 | +$16.8M | |
| 2 | +$12.9M | |
| 3 | +$7.83M | |
| 4 |
Mirum Pharmaceuticals
MIRM
|
+$6.46M |
| 5 |
Ocular Therapeutix
OCUL
|
+$5.95M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$22.6B
| $226M | 40.13% |
8,166,047
|
|
||
2
argenx
ARGX
$54.6B
| $26.8M | 4.76% |
36,718
+10,718
|
|
||
3
Insmed
INSM
$20.8B
| $25.8M | 4.57% |
157,500
-109,500
|
|
||
|
ONC
4
BeOne Medicines Ltd
ONC
$28B
| $23.9M | 4.24% |
80,542
+11,230
|
|
||
|
5
Cogent Biosciences
COGT
$5.9B
| $22.9M | 4.07% |
596,000
+278,628
|
|
||
|
6
Mirum Pharmaceuticals
MIRM
$6.53B
| $21.2M | 3.77% |
230,000
-68,682
|
|
||
|
BLTE
7
Belite Bio
BLTE
$5.86B
| $18.6M | 3.3% |
+116,684
|
|
||
8
Legend Biotech
LEGN
$5.19B
| $17.9M | 3.18% |
+990,000
|
|
||
9
Nektar Therapeutics
NKTR
$2.06B
| $15.1M | 2.68% |
+210,000
|
|
||
|
DBVT
10
DBV Technologies
DBVT
$919M
| $14.5M | 2.57% |
693,534
+334,484
|
|
||
11
Pharvaris
PHVS
$2.29B
| $13.9M | 2.47% |
493,000
-49,696
|
|
||
|
ABVX
12
Abivax
ABVX
$7.91B
| $13.5M | 2.4% |
121,245
-8,755
|
|
||
13
Xenon Pharmaceuticals
XENE
$5.11B
| $13.2M | 2.34% |
227,000
+90,500
|
|
||
14
Celcuity
CELC
$4.28B
| $10.8M | 1.92% |
95,000
-25,000
|
|
||
15
EyePoint Inc
EYPT
$1.14B
| $10.2M | 1.82% |
795,000
+15,000
|
|
||
|
16
Merck
MRK
$281B
| $9.62M | 1.71% |
+80,000
|
|
||
17
Arcutis Biotherapeutics
ARQT
$3.28B
| $9.44M | 1.67% |
400,645
+190,645
|
|
||
18
Allogene Therapeutics
ALLO
$690M
| $8.42M | 1.49% |
3,450,000
-1,513,756
|
|
||
19
Kymera Therapeutics
KYMR
$7.44B
| $8.33M | 1.48% |
100,000
-39,000
|
|
||
20
Dianthus Therapeutics
DNTH
$4.51B
| $7.88M | 1.4% |
93,882
-56,118
|
|
||
21
Enliven Therapeutics
ELVN
$3.15B
| $7.84M | 1.39% |
200,000
-108,141
|
|
||
22
Perspective Therapeutics
CATX
$336M
| $6.78M | 1.2% |
1,625,000
+492,185
|
|
||
|
DFTX
23
Definium Therapeutics
DFTX
$2.67B
| $6.26M | 1.11% |
+331,000
|
|
||
24
Harrow
HROW
$1.6B
| $5.83M | 1.03% |
165,209
+158,178
|
|
||
25
Protara Therapeutics
TARA
$224M
| $5.37M | 0.95% |
+1,030,846
|
|